Payment overview · 2025
General Payments
$1,438.55
92 reported records · 27 companies
Healthcare provider profile · identity verified
Kimpreet Aulakh, MD
Allopathic & Osteopathic Physicians|Internal Medicine · FRESNO, CA · NPI 1104121524
Verified facts
What the public records show
CMS Open Payments records show Kimpreet Aulakh, MD received $1,438.55 in general payments during 2025 across 92 reported records.
Amgen Inc. accounted for 29.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 41 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic, Paxlovid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 123 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 123 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Wegovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $429.75 | 29.9% | 46 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $200.45 | 13.9% | 9 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $108.46 | 7.5% | 5 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $54.82 | 3.8% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $53.12 | 3.7% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $52.81 | 3.7% | 3 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $48.56 | 3.4% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $44.72 | 3.1% | 2 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $43.84 | 3.0% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $38.61 | 2.7% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $26.54 | 1.8% | 1 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $25.82 | 1.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $25.32 | 1.8% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $25.30 | 1.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $24.98 | 1.7% | 1 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $24.81 | 1.7% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $24.67 | 1.7% | 1 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $24.22 | 1.7% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $21.76 | 1.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $21.61 | 1.5% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $21.15 | 1.5% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $19.53 | 1.4% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $17.42 | 1.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.98 | 1.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.66 | 1.1% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $15.10 | 1.1% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $13.54 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,438.55 | 92 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $329.77 | 41 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $329.77 | 41 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $179.44 | 8 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $99.98 | 5 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $99.98 | 5 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $69.65 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $69.65 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $69.65 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $61.67 | 2 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $54.82 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $53.12 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $53.12 | 2 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $48.56 | 2 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc., Eisai Inc. | $44.83 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $44.72 | 2 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $43.84 | 2 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $43.84 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $38.61 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $36.41 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $26.54 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka Pharmaceutical Development & Commercialization, Inc. | $25.82 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $25.32 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $24.98 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $24.81 | 1 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $24.67 | 1 | 2025 |
Source payment records
|
|||||
| THINPREP 2000 PROCESSOR Normalized: thinprep 2000 processor |
Device | Hologic Sales and Service, LLC | $24.67 | 1 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $24.22 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $21.76 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $21.61 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $21.61 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $21.15 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $19.91 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $19.91 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $18.90 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $17.42 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $17.42 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.63 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.75 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15.66 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $15.10 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $13.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 123 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 88 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 19 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
39 | 11 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
123 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
123 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
88 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
136 | 23 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
19 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 833 | 228 |
| Levothyroxine Sodium | Levothyroxine Sodium | 587 | 146 |
| Amlodipine Besylate | Amlodipine Besylate | 508 | 140 |
| Losartan Potassium | Losartan Potassium | 474 | 128 |
| Lisinopril | Lisinopril | 404 | 112 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 343 | 108 |
| Omeprazole | Omeprazole | 334 | 100 |
| Metformin Hcl | Metformin Hcl | 328 | 86 |
| Metoprolol Succinate | Metoprolol Succinate | 273 | 79 |
| Gabapentin | Gabapentin | 262 | 67 |
| Alendronate Sodium | Alendronate Sodium | 240 | 70 |
| Sertraline Hcl | Sertraline Hcl | 208 | 63 |
| Hydrochlorothiazide | Hydrochlorothiazide | 205 | 61 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 199 | 50 |
| Simvastatin | Simvastatin | 173 | 46 |
| Pantoprazole Sodium | Pantoprazole Sodium | 163 | 46 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 160 | 76 |
| Montelukast Sodium | Montelukast Sodium | 155 | 44 |
| Carvedilol | Carvedilol | 150 | 42 |
| Eliquis | Apixaban | 136 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 133 | 51 |
| Jardiance | Empagliflozin | 123 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 116 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 113 | 28 |
| Furosemide | Furosemide | 113 | 37 |
| Famotidine | Famotidine | 112 | 38 |
| Allopurinol | Allopurinol | 109 | 28 |
| Potassium Chloride | Potassium Chloride | 90 | 24 |
| Trazodone Hcl | Trazodone Hcl | 89 | 25 |
| Valsartan | Valsartan | 89 | 22 |
| Ozempic | Semaglutide | 88 | 16 |
| Tramadol Hcl | Tramadol Hcl | 85 | 26 |
| Atenolol | Atenolol | 84 | 27 |
| Ezetimibe | Ezetimibe | 77 | 25 |
| Alprazolam | Alprazolam | 75 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 74 | 20 |
| Benazepril Hcl | Benazepril Hcl | 71 | 17 |
| Bupropion Xl | Bupropion Hcl | 70 | 18 |
| Metformin Hcl Er | Metformin Hcl | 64 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 63 | 15 |
| Glipizide | Glipizide | 63 | 20 |
| Meloxicam | Meloxicam | 62 | 27 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 58 | 14 |
| Baclofen | Baclofen | 57 | 25 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 56 | 21 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 55 | 46 |
| Paroxetine Hcl | Paroxetine Hcl | 55 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 54 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 54 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 51 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 50 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 50 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 49 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 47 | suppressed |
| Ibuprofen | Ibuprofen | 44 | 21 |
| Prednisone | Prednisone | 43 | 33 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 41 | 34 |
| Solifenacin Succinate | Solifenacin Succinate | 41 | 13 |
| Irbesartan | Irbesartan | 40 | 11 |
| Synthroid | Levothyroxine Sodium | 39 | 11 |
| Naproxen | Naproxen | 38 | 16 |
| Azithromycin | Azithromycin | 37 | 32 |
| Estradiol | Estradiol | 37 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 37 | 27 |
| Trulicity | Dulaglutide | 37 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 34 | 11 |
| Lorazepam | Lorazepam | 32 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 32 | 14 |
| Ketoconazole | Ketoconazole | 31 | 22 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 31 | suppressed |
| Celecoxib | Celecoxib | 30 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 30 | suppressed |
| Acyclovir | Acyclovir | 29 | suppressed |
| Spironolactone | Spironolactone | 29 | suppressed |
| Rybelsus | Semaglutide | 28 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 28 | suppressed |
| Telmisartan | Telmisartan | 28 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 28 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 27 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 27 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 25 | suppressed |
| Chlorthalidone | Chlorthalidone | 25 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 25 | suppressed |
| Entresto | Sacubitril/Valsartan | 25 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 24 | 14 |
| Glimepiride | Glimepiride | 24 | suppressed |
| Linzess | Linaclotide | 24 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | 11 |
| Lovastatin | Lovastatin | 23 | suppressed |
| Pregabalin | Pregabalin | 23 | suppressed |
| Premarin | Estrogens, Conjugated | 23 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 22 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 14 |
| Ibandronate Sodium | Ibandronate Sodium | 20 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Wegovy | Semaglutide | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 19 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 18 |
| Rizatriptan | Rizatriptan Benzoate | 19 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Finasteride | Finasteride | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Repatha Sureclick | Evolocumab | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Nystatin | Nystatin | 16 | 11 |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | 13 |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | 11 |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Praluent Pen | Alirocumab | 12 | suppressed |
| Qulipta | Atogepant | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,438.55 · 92 records | Amgen Inc. | ABRYSVO, AFREZZA, AMVUTTRA, APTIMA, AREXVY, BREZTRI, CAPLYTA, CAPVAXIVE, COMIRNATY, EVENITY, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, Fintepla, Fluad, Flucelvax, GARDASIL 9, Heplisav-B, IBSRELA, JARDIANCE, Kerendia, LEQEMBI, LEQVIO, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, PREVNAR 20, PROLIA, REPATHA, REXULTI, SHINGRIX, THINPREP 2000 PROCESSOR, The Cologuard Plus Collection Kit, UBRELVY, Veozah, ZAVZPRET, ZEPBOUND, ZORYVE | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error